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Objectives. We sought to assess if ineligibility to coronary artery bypass grafting (CABG) constitutes a risk factor in patients
who underwent a nonemergent unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with
prophylactic Impella heart pump support. Background. ULMCA PCI in patients not deemed eligible for CABG is associated with
significantly worse outcomes compared to ULMCA PCI in eligible patients. Methods. Patients from the cVAD Registry and the
PROTECT II trial who underwent a nonemergent ULMCA PCI were identified. We compared in-hospital mortality and major
adverse cardiac and cerebrovascular event (MACCE) rates as well as 30-day survival and MACCE rates between CABG ineligible
and CABG eligible patients. Results. A total of 331 patients were included (293 Impella 2.5, 38 Impella CP); 227 were ineligible
for CABG and 104 were eligible. Baseline characteristics were remarkable for a trend toward higher rate of chronic obstructive
pulmonary disease in the ineligible patients. In-hospital mortality (3.52% vs. 5.77%; p=0.383) and MACCE (6.61% vs. 7.69%;
p=0.816) rates as well as 30-day survival (92.0% vs. 93.4%; Log-Rank p-value =0.781) and MACCE (88.1% vs. 90.1%; Log-Rank
p-value=0.648) rates were not different between the two groups. Conclusions. The results of our study suggest that prophylactic
Impella support appears to mitigate the risks inherent to surgical ineligibility in patients undergoing a nonemergent ULMCA PCI.
Our results require further investigation.
1. Introduction
The outcomes of percutaneous coronary intervention (PCI)
and coronary artery bypass grafting (CABG) surgery for
the treatment of left main coronary artery (LMCA) disease
have been studied in recent randomized controlled trials
[1, 2] and meta-analyses at the population-level data [3–5]
as well as the individual patient-level data [6]. Although this
coronary lesion is relatively infrequent at approximately 5%
prevalence [7], LMCAPCI revascularization has experienced
wider adoption and a significant improvement in outcomes
[8].
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Acute improvement in clinical outcomes has been
demonstrated for PCI over CABG; however, the long-term
results reveal clinical equipoise between the two strategies
[1, 3]. Indeed, while repeat revascularization rates are still in
favor of the CABG strategy, stroke rates are in favor of the
PCI strategy. This holds true even in the subgroup of patients
with LMCA disease as shown in the most recently published
meta-analyses of randomized controlled trials [4, 5].
A PCI revascularization strategy is an acceptable alter-
native to CABG for patients with coronary disease of low
and intermediate complexity, but the European and U.S.
guidelines recommend CABG for those with high complexity
coronary disease [9, 10]. Encouraging results from theEXCEL
trial suggest that PCI is perhaps a preferred alternative to
CABG in selected patients with LMCA disease who are
candidates for either procedure [2]. Patients enrolled in
this large-scale and well-conducted trial had a mean left
ventricular ejection fraction (LVEF) above 56% at baseline,
the overall use of hemodynamic support devices was less
than 5%, and 100% were eligible to both revascularization
strategies. Conversely, patients enrolled in the PROTECT II
trial [11] had a mean LVEF below 24%, at least 64% were
not surgical candidates, and per study protocol and according
to enrolling investigators all the patients requiring hemody-
namic support represent a sicker patient population. These
higher risk patients, especially those ineligible for surgical
revascularization, are not often studied and their outcomes
are not well referenced or benchmarked. Indeed, several
studies have shown that surgical ineligibility is associated
with increased mortality in patients undergoing PCI on a
diseased unprotected left main coronary artery (ULMCA)
[12, 13]. More recently Sukul et al. demonstrated in a larger
study no difference in outcomes between surgically ineligible
patients and the rest of the patients who underwent PCI,
except in the subgroup of patients who underwent PCI on
ULMCA [14]. In these patients, surgical ineligibility was
associated with significantly higher and unacceptable in-
hospital mortality as high as 20%.
In this study, we sought to compare the outcomes of high-
risk patients deemed ineligible for surgical revascularization
and those eligible ones who underwent prophylactic support
with Impella heart pump for a nonemergent PCI on an
ULMCA. The study results were presented as a poster in
the Journal of American College of Cardiology in March
2018.
2. Methods
2.1. Patient Population. All consecutive patients enrolled
in the cVAD Registry (catheter based ventricular assist
device registry) who underwent prophylactic hemodynamic
support with Impella heart pump prior to a nonemergent
PCI on an ULMCA were analyzed. In addition, similar
patients enrolled in the PROTECT II trial [4] were included
as well. The respective institutional review board of the
sites participating in the cVAD registry reviewed the study
protocol and authorized an informed consent waiver for
the retrospective data extracted from the chart of patients
included in this analysis. All the patients enrolled in the
Protect II randomized controlled trial provided informed
consent.
Investigators were asked to report in the case report form
(CRF) of the aforementioned studies the recommendations
of a surgical consultation when it occurred. The reason
for ineligibility was not reported. In the PROTECT II trial
investigators were asked to request a surgical consultation to
prospectively assess patient eligibility for CABG. Although
the CRF sections regarding surgical eligibility are identical
in both the PROTECT II trial and the cVAD Registry, in
the latter the investigators and the staff chart abstractor at
each site reviewed the patient charts including admission
notes, consult notes, nursing notes, catheterization report,
and discharge summary to identify and report the documen-
tation of surgical ineligibility at any time before PCI. In our
study, patients were considered ineligible for CABG when
ineligibility was documented in the patient chart whether a
surgical consultation occurred or not. All remaining patients
were considered eligible for CABG including those who
declined CABG following a surgical consultation recom-
mending surgery. Patients who underwent an emergent PCI
with or without cardiogenic shock and patients with history
of CABG were excluded from this analysis.
2.2. Study Endpoints. The primary endpoint measured was
all-cause in-hospital mortality rate. The secondary endpoint
included in-hospital rate of major adverse cardiac and
cerebrovascular events (MACCE) defined as death, stroke,
myocardial infarction, and repeat revascularization with
PCI or CABG. A Kaplan-Meier analysis was performed to
estimate the 30-day MACCE and survival rates.
2.3. Device. The Impella 2.5 and Impella CP devices
(Abiomed Inc., Danvers, Massachusetts, USA) are 12 French
(Fr) and 14 Fr, respectively, microaxial pumps mounted on a
9 Fr catheter. They are inserted through the femoral artery
using a modified Seldinger technique. The pump is advanced
retrogradely across the aortic valve into the left ventricle
under fluoroscopy guidance. Impella 2.5 and Impella CP
devices can generate up to 2.5 L/min and 4.0 L/min of
forward flow, respectively, directly in the ascending aorta.
Heparinized dextrose fluid is purged through the pump
and released in the general circulation at a rate of 4 – 12
mL/hr to prevent clot formation in the motor and early
pump wear. The manufacturer recommends an activated
thrombin time (ACT) of 160–180 seconds during pump
support.
2.4. Statistical Analysis. Data are expressed as mean ±
standard deviation (SD) or median with quartiles or fre-
quencies as appropriate. A two-tailed unpaired t-test was
used for parametric two-group comparisons on continuous
variables. Alternatively, a Mann-Whitney test was used if
the assumption of the normality of the distribution for the
continuous variable could not be established. Pearson’s 𝜒2
test or Fisher exact test was used as appropriate for nominal
data. In-hospital mortality is reported as the proportion of
patients that were expired during the index hospitalization.
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Figure 1: Kaplan-Meier analysis of estimated 30-day survival rate and freedom from MACCE rate. MACCE: major adverse cardiac and
cerebrovascular events (death, stroke, myocardial infarction, and repeat revascularization).
A Kaplan-Meier estimate with a log-rank test was used to
compare MACCE and survival rates up to 30 days between
the ineligible patient group and the eligible patient group.
Surviving patients were censored at 30 days or last known
follow-up, whichever is earlier in this analysis. In order to
identify potential confounding factors, a Cox proportional
hazard regression for 30-day mortality and 30-day major
adverse cardiac and cerebrovascular events (MACCE) was
conducted. The model included covariates with a p value of
0.1 or less identified in the baseline characteristic compar-
ative analysis between eligible and ineligible groups. All p-
values were two-tailed and considered significant when the
probability was less than 0.05. The statistical analyses for this
report were performed using a JMP 10 software package (SAS
Institute Inc., Cary, NC).
3. Results
A total of 331 patients, 297 consecutive patients from the
cVAD Registry (supported between July 2008 and May
2015) and 34 from the PROTECT II trial (supported between
January 2008 and October 2010), who underwent prophy-
lactic hemodynamic support with an Impella heart pump
(293 Impella 2.5, 38 Impella CP) for a nonemergent PCI
on an ULMCA were included. Of the 331 patients, 227 were
ineligible for surgical revascularization and 104 were eligible.
The baseline and procedural characteristics of the two groups
were not different with the exception of a significantly higher
rate of history of AICD/pacer implanted in the eligible
patients and a trend toward higher rate of chronic obstructive
pulmonary disease (COPD) in the ineligible patients. The
baseline characteristics are presented in Table 1 and the
procedural characteristics in Table 2.
The in-hospital mortality was not significantly different
between the ineligible group and the eligible group (3.52%
vs. 5.77%; p = 0.383). Furthermore, there was no difference
between the two groups with regard to in-hospital MACCE
(6.61% vs. 7.69%; p= 0.816) (Table 3), 30-day MACCE rate
(88.1% vs. 90.1%; Long-Rank p-value = 0.648), or 30-day
survival rate (92.0% vs. 93.4%; Long-Rank p-value = 0.781)
(Figure 1). There were no differences in other in-hospital
outcomes reported by the sites (Table 3).
4. Discussion
The present study of high-risk patients who underwent a
nonemergent PCI on an ULMCA demonstrates that surgical
ineligibility is not associated with worse in-hospital outcomes
or worse 30-day survival when prophylactic support with
Impella heart pump is undertaken.
Temporal trends of revascularization strategies in
ULMCA stenosis reported recently by Park et al. show that
more patients with ULMCA disease receive PCI and the
gap in the treatment effect between PCI and CABG has
decreased despite worsening of patient comorbidities and
ULMCA stenosis complexity over time [8]. Furthermore, the
advent of minimally invasive, potent, and rapidly deployable
percutaneous left ventricular assist devices, such as the
Impella heart pumps, has enabled interventional cardi-
ologists to safely and effectively treat patients presenting
with high-risk features for periprocedural complications
[11].
Indeed, Schreiber et al. [15] reported recently a single-
center experience which demonstrated favorable in-hospital
and 30-day survival (98.43% and 97.74%, respectively) among
patients with depressed LV function (28.74±15.55%) and
multiple comorbidities (Society of Thoracic Surgeon (STS)
morbidity score of 23.6±12.04) who underwent prophylactic
Impella support for a ULMCA PCI. The predicted surgical
mortality estimated by the STS score in these patients was
lower than the STS mortality score of our patients (3.59±3.63
vs. 6.06±6.57), suggesting a less sick patient population
who might have been eligible for surgical revasculariza-
tion.
Prior studies have demonstrated that complex patients
with ULMCA disease or multivessel coronary artery disease
4 Journal of Interventional Cardiology
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(CAD) who are ineligible for surgical revascularization have
worse outcomes following a nonemergent PCI than those
eligible for surgical revascularization [1, 2]. However, it is
worth noting that these studies reported either a paucity of
or no patients supported with percutaneous ventricular assist
devices (pVAD).A recent study, conducted by Sukul et al. and
including 99,370 patients who underwent a nonemergent PCI
(<2% pVAD use) between June 2010 and December 2014 at
33 hospitals with on-site cardiac surgery, showed that PCI in
surgical ineligible patients was generally safe except among
patients who underwent ULMCA PCI. In this ULMCA
PCI subgroup, surgically ineligible patients experienced sig-
nificantly higher in-hospital mortality compared to non-
ineligible patients (20.0% vs. 5.3%, p=0.02) and significantly
higher incidence of cardiogenic shock during or following
the index nonemergent PCI (25.0% vs. 5.1%, p=0.004) [3].
In contrast, when comparing outcomes between surgically
ineligible patients in our study and those included in the
Sukul et al., we find that our patients had significantly lower
in-hospital mortality rate (3.5% vs. 20.0%, p=0.001). Further-
more, mortality rate in our entire cohort was comparable to
that of the non-ineligible patients who underwent ULMCA
PCI in the Sukul et al. report (6.9% vs. 5.3%, p=0.73). These
comparisons suggest that prophylactic Impella supportmight
be associated with improved in-hospital survival in patients
ineligible for surgical revascularization probably by reducing
the occurrence of cardiogenic shock during or following an
ULMCA PCI.
In our study the baseline and procedural characteristics
of the surgically ineligible and the surgically eligible patients
were not different. A relevant exceptionwas a trend (p=0.068)
toward higher rate of COPD in the surgically ineligible
patients. Conversely, the most recent landmark studies com-
paring the impact of surgical ineligibility in nonemergent
ULMCA PCI showed that ineligible patients present with
higher comorbid risk factors [12, 13].
Indeed, it has been shown that registries are usually not
well designed to characterize surgically ineligible patients and
often do not capture the reason for ineligibility [12–14].
McNulty et al. addressed the limitations of registries for ade-
quate documentations of surgical candidacy and selection
biases in nonemergent LMCA stenting. These investigators
found that poor targets or conduits, cachexia or frailty, and
malignancy were the most frequently reported reasons for
ineligibility to CABG. However, these risk factors were not
captured in our study. Other frequent reasons for ineligibility
included advanced age, severe systolic dysfunction, and renal
insufficiency. These were well balanced between the two
groups in our study, probably because they represent themain
risk factors that lead the physician to initiate prophylactic
Impella support. Furthermore, in terms of risk assessment, it
appears that features that connote surgical risk do not nec-
essarily overlap with features defining PCI patients at high
risk for periprocedural complications. Indeed, advanced age,
severe lung disease, poor targets, severe systolic dysfunction,
or renal insufficiency does not necessarily constitute a con-
traindication to PCI, especially if the patient undergoes pro-
tected PCI with prophylactic mechanical circulatory support
[11].
5. Limitations
Several limitations regarding this study need to be considered
when interpreting our results. First, the case report form of
both the cVAD registry and the PROTECT II trial captured
patient eligibility for surgical revascularization; however, the
reasons for ineligibility were not captured. Second, although a
surgical consultation was requested for a majority of patients
included in this study, the remainder were considered by
default as eligible for surgical revascularization in absence of
additional patient information indicating ineligibility. Third,
the low rate of events in conjunction with the sample size
of our study does not confer an adequate statistical power
to detect a difference between the two groups. Fourth, the
retrospective and observational design of our study precludes
us from drawing anything more than inferences and associ-
ations between the surgical status and the outcomes. Fifth,
patient selection bias cannot be excluded due to differences
in practice at enrolling sites and due to differences between
patients enrolled in the cVAD and Protect II. Finally, a
Cox proportional hazard regression conducted to identify
potential confounding factors between the two groups did not
identify any covariates associated with increased risk of death
or MACCE at 30 days.
6. Conclusion
The results of our study suggest that prophylactic Impella
support mitigates the risks inherent to surgical ineligibility
in patients undergoing a nonemergent ULMCA PCI. Our
results require further investigation, as more surgical ineli-
gible patients need ULMCA PCI.
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